Cwm LLC Increases Stock Holdings in Stryker Co. (NYSE:SYK)

Cwm LLC lifted its stake in shares of Stryker Co. (NYSE:SYKFree Report) by 3.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,476 shares of the medical technology company’s stock after buying an additional 497 shares during the quarter. Cwm LLC’s holdings in Stryker were worth $5,180,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of SYK. Burkett Financial Services LLC purchased a new position in shares of Stryker during the fourth quarter worth about $25,000. Farmers & Merchants Trust Co of Chambersburg PA grew its position in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares during the last quarter. Rogco LP purchased a new stake in shares of Stryker in the fourth quarter valued at about $30,000. DSM Capital Partners LLC acquired a new position in Stryker during the 4th quarter worth approximately $34,000. Finally, HBC Financial Services PLLC purchased a new position in Stryker in the fourth quarter worth $37,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

SYK traded up $3.97 during trading on Wednesday, reaching $348.67. The stock had a trading volume of 839,609 shares, compared to its average volume of 1,184,369. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $132.83 billion, a price-to-earnings ratio of 39.80, a price-to-earnings-growth ratio of 2.71 and a beta of 0.92. The stock has a 50 day moving average of $336.74 and a two-hundred day moving average of $331.10. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41.

Stryker (NYSE:SYKGet Free Report) last posted its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.14 earnings per share. As a group, equities analysts anticipate that Stryker Co. will post 11.95 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.92%. The ex-dividend date is Friday, June 28th. Stryker’s dividend payout ratio (DPR) is currently 36.53%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SYK. Barclays upped their price objective on Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a research report on Thursday, May 2nd. UBS Group increased their price objective on shares of Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a report on Wednesday, May 1st. BTIG Research boosted their target price on shares of Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. TD Cowen increased their price objective on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Finally, Royal Bank of Canada increased their price target on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $370.58.

View Our Latest Stock Report on Stryker

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Further Reading

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.